The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    Including Jazz’s planned acquisition of Actio, nearly two dozen privately held drugmakers have been purchased this year in deals with at least $50 million in guaranteed proceeds.

    Updated Aug. 10, 2026
  • A white building entrance sign reads "Bristol Myers Squibb," with a barbed fence behind it surrounded by flowers.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

    The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

    The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

  • Illustration of lung cancer
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    New Taiho, Cullinan data heats up lung cancer drug battle

    The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Drug startups have banked $6 billion in IPOs so far in 2026, more than the combined amount raised by this point in the previous four years.

    Updated Aug. 7, 2026
  • A photo depicting a vial of Eli Lilly's obesity drug retatrutide and a syringe.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

    Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

  • A rendering of an adeno-associated virus, colored blue-green, on a black background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    PTC takes a chance on Sangamo’s Fabry disease gene therapy

    Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.

  • psychedelic brain
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Psychedelics developer Definium scores more positive data for LSD pill

    Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    At least seven biotechs have announced venture fundings since Monday, representing the busiest calendar week in two months among the investment firms BioPharma Dive tracks.

    Updated Aug. 13, 2026
  • An illustration of lymphocytes
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Boulevard starts up with $65M to pursue targeted autoimmune drugs

    Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

  • President Trump holding up an executive order on vaccines.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Vaccines

    Trump signs order seeking to upend childhood vaccine schedule

    The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.

    FDA
  • A close-up of a child's hands with red, irritated skin on the wrist.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

    Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    A new BioPharma Dive analysis shows that, in 2026, drugmakers are paying considerably more for rights to China-based medicines than they were last year.

    Updated Aug. 14, 2026
  • A person works in Sionna Therapeutics' lab.
    Image attribution tooltip
    Permission granted by Sionna Therapeutics
    Image attribution tooltip

    Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

    Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

    Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

  • gene editing crispr cartoon
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A // Gene editing

    Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

    The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years. 

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire.

    BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.

    Updated Aug. 4, 2026
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

    Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

  • This image shows a digital illustration of red blood cells flowing through a blood vessel. The red blood cells are shown in a close-up view, and the vessel is shown as a red, translucent tube.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Vaderis hauls in $152M to test an AKT-targeting drug

    The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.

  • a photo of Epicrispr Biotechnologies CEO Amber Salzman standing in a white lab coat facing the camera with a woman behind her to her left in a white lab coat with black glasses holding a tube and syringe, and a woman in a white labcoat behind to the right facing the right touching lab tools.
    Image attribution tooltip
    Permission granted by Epicrispr Biotechnologies
    Image attribution tooltip
    Emerging biotech

    Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

    The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.

  • A sign for Jazz Pharmaceuticals is displayed at the ASCO annual meeting in Chicago on June 2, 2018.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

    Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.

  • Europe's JUPITER supercomputer. Big pharma companies are racing to use AI and supercomputing in drug R&D
    Image attribution tooltip
    Sascha Schuermann/Getty Images via Getty Images
    Image attribution tooltip

    Why Big Pharma is chasing the industry’s most-powerful supercomputer

    Bristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.

  • The building features a modern glass façade with the Nasdaq logo prominently displayed. Surrounding the structure are other commercial buildings and digital billboards, which are characteristic of the vibrant Times Square environment.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Pain drugs

    Latigo IPO raises nearly $350M for pain drug development

    The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

  • Close up of eye with retina visible
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

    Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.” 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

    Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.